To find out more about the podcast go to The global fallout of RFK Jr's vaccine policies.
Below is a short summary and detailed review of this podcast written by FutureFactual:
RFK Jr, Gavi, and Guinea-Bissau: The Global Public Health Fallout of US Vaccine Policy
In this episode of Shortwave, NPR explores how changes in US vaccine priorities under RFK Jr are reverberating globally. The first case examines a funding ultimatum to Gavi, the international vaccine alliance, tied to removing thimerosal from vaccines. The second examines a contentious hepatitis B vaccine study in Guinea-Bissau, partly funded by the US, which has sparked ethical debates and raised questions about research in resource-poor settings. The discussion suggests the United States is increasingly isolated in global public health leadership, signaling potential shifts in who leads the world in health policy and ethics.
Introduction and framing
The episode from NPR’s Shortwave analyzes how US vaccine priorities under RFK Jr are shaping global public health conversations. Gabriela Emanuel presents two concrete examples where US policy moves are creating global controversy: the ultimatum to Gavi and a hepatitis B newborn vaccine study in Guinea-Bissau, funded in part by the US. The conversation includes perspectives from vaccine experts and global health bodies and raises questions about ethics, science, and leadership on the world stage.
"The US is getting more isolated when it comes to public health, being called out publicly as supporting things that are unethical or go against science" - Gabriela Emanuel
Case study 1: Gavi ultimatum over thimerosal
The US, under RFK Jr’s team, has pressed Gavi to remove thimerosal from vaccines, arguing for changes to be guided by scientific consensus and the board’s decisions. Thimerosal, a preservative containing mercury, has been deemed safe by major health organizations, but the policy dispute centers on whether to phase it out in lower-income countries, where multi-dose vials are common and single-dose vials are expensive. The discussion underscores how political pressure can influence international funding and vaccine availability, with potential consequences for millions of children.
"The World Health Organization, the US Food and Drug Administration, and the US Centers for Disease Control and Prevention have all deemed it safe" - Angela Rasmussen
Case study 2: Guinea-Bissau hepatitis B trial and ethical concerns
Guinea-Bissau has high hepatitis B prevalence, and the current policy vaccinates newborns a few weeks after birth. Denmark-funded researchers, with US support, proposed a large study to vaccinate at birth in half the cohort and delay in the other half, to compare outcomes. Critics argue this could withhold proven protection from some infants, invoking comparisons to the Tuskegee era to highlight potential ethical pitfalls. Supporters say the study would answer valuable questions about vaccine timing and safety, and that the trial would still provide care to all participants.
"The first and important consideration in making a study ethical is that it's answering a valuable question" - Christine Grady
Ethics, responses, and global health implications
Ethical scrutiny has intensified, with WHO calling the Guinea-Bissau study unethical for exploiting scarcity and resources. CDC and HHS defend the study as the gold standard, while critics warn of potential harm and distrust in healthcare systems. The panel notes a broader shift in global health leadership, suggesting that the US may be re-positioning itself in relation to international norms and scientific consensus.
"The WHO even called it unethical, which is pretty extreme language for a very kind of subdued, careful group" - Gabriela Emanuel
Takeaways and broader context
Across these debates, the episode contends that the US is becoming more isolated in public health, challenging traditional leadership dynamics and raising questions about how science and ethics should guide global health policy in the years ahead.
"We may be at the beginning of a kind of shift in the balance of power of who leads the world, at least from a public health perspective" - Gabriela Emanuel
